The Business Times
business-time-50
SUBSCRIBERS

Temasek leads US$85m investment round for gene therapy startup

google-preferred-sourceAdd BT as a preferred source
Published Tue, Feb 26, 2019 · 09:50 PM

DeeperDive is a beta AI feature. Refer to full articles for the facts.

Singapore

IMMUNE cell gene therapy startup Gracell Biotechnologies has raised US$85 million through a Series B round led by Singapore government investment firm Temasek Holdings.

Also taking part in the financing round were Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji.

Temasek

Copyright SPH Media. All rights reserved.

Reuse this contentFeedback

TRENDING NOW

Andrew Lee, chairman of OCBC (right), and group chief executive Tan Teck Long speaking at Thursday's (Apr 16) AGM.

Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman

Marco Beltgens, assistant vice-president of global franchising for the Asia-Pacific at Enterprise Mobility, with Charmain Kwee, group executive director of Eurokars Group.

Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore

The iconic rainbow blocks of Rochor Centre were demolished in 2018 to 2019 to make way for the North-South Corridor.

20 photos that show how dramatically Singapore has changed in two decades

Key exports to all but four of Singapore’s top 10 markets have risen in March.

Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More